Medical News

RSS

AIDS programs reach out to African immigrant community

The Seattle Times reports on educating people about AIDS in the African immigrant community in Seattle.

9 Sep 2010

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology. Flutemetamol is an investigational positron emission tomography (PET) imaging agent being developed by GE Healthcare, in the field of brain imaging.

9 Sep 2010

Opinions: U.S. commitment to Global Fund; Innovative financing; Global food security; Aid for Pakistan

A Times of Trenton editorial looks at the work of the Global Fund to Fight AIDS, Tuberculosis and Malaria, which is "estimated to have already saved 5 million lives, enables programs that prevent and treat infections, eliminate the transmission of HIV from pregnant women to their unborn children, contain the threat of multidrug-resistant TB, and eliminate malaria as a public health problem."

9 Sep 2010

ResMed completes two-for-one stock split of common stock

ResMed Inc. announced today that its two-for-one stock split of the company's outstanding shares of common stock, payable in the form of a 100% stock dividend was completed on August 30, 2010.

From ResMed Corp 9 Sep 2010

Severe eye problems at cattle show

After nearly fifty people complained of serious eye irritations, the dairy cow pavilion at the Royal Adelaide Show has been closed down. Organizers are blaming stagnant urine for the irritations. St John Ambulance volunteers were called to the Dairy Cattle pavilion after some people reported irritation to their eyes. 30 people required treatment at the site. 20 more people reported to the emergency department of the Royal Adelaide Hospital where their eyes were washed.

8 Sep 2010

Flood victims in Pakistan helped by Australian health team

Hundreds of Pakistani flood victims have been treated at an Australian health centre set up in the country last week. This center at the Punjab city of Kot Addu is manned by a team of doctors, nurses and paramedics from the Northern Territory, Western Australia, Victoria and Queensland.

8 Sep 2010

Neck manipulation may be risky without significant benefits: Study

According to new research manipulation for neck pain may carry a risk of serious injury, including stroke. For the study more than 120 patients with neck pain were included. They were randomly assigned to be treated with either manipulation or mobilization - which involves small, rhythmic movements applied to stiff or inflamed tissue. The outcome of both groups was almost identical, prompting researchers to conclude that manipulation may not be worth the risk.

8 Sep 2010

Cocaine use on the rise in Australia

The number of cocaine abuse related arrests has risen in Sydney's CBD and an increasing number of users of the drug are being treated in hospitals. According to the latest NSW Bureau of Crime Statistics and Research figures arrests for possession and use of the drug have risen by 76.6 per cent in the past two years.

8 Sep 2010

Shared needle at school science experiment puts students at risk

In a science experiment at a Tasmanian Dover District high school, a teacher took blood samples from grade 9 and 10 students using the same needle. They were testing blood pH levels. Now students are being tested for HIV infection. The needle was dipped in methylated spirits each time before pricking but authorities say this is not enough to prevent transmission of HIV and other viruses like Hepatitis B and C.

8 Sep 2010

PositiveID to sell Health Link personal health record business to Health Plexus

PositiveID Corporation announced today that it has agreed to sell its Health Link personal health record business for $1 million to Health Plexus, LLC. The Company will also retain the right to royalties on future Health Link revenues. Health Link is the Company's web-based personal health record (PHR), which is non-core to the Company's primary HealthID division. HealthID develops and markets unique medical devices, with a focus on diabetes management, and rapid medical testing products.

8 Sep 2010

OEFI selects HealthEdge's HealthRules product suite

HealthEdge, provider of the only modern, enterprise-class software platform for healthcare payors, today announced that the Pasadena, Calif.-based Operating Engineers Funds Inc. (OEFI) has selected the patented HealthRules product suite to tackle the non-profit health plan's unique and challenging service needs.

8 Sep 2010

BioSpace, Delaware BioScience partner to launch online career center for life science markets

BioSpace has partnered with the Delaware BioScience Association to launch an online career center specifically for life science markets.

8 Sep 2010

NEXUS Biosystems acquires REMP from Tecan Group

NEXUS Biosystems, Inc., a leading innovator and worldwide provider of automated sample management systems, today announced the completion of the acquisition of REMP AG of Switzerland, a wholly-owned subsidiary of the Tecan Group.

From Tecan 8 Sep 2010

Zyngenia completes $15M Series A financing extension from NEA

Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.

8 Sep 2010

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.

8 Sep 2010

BioMed Realty Trust expands San Diego property portfolio to 1.8M rentable square feet

BioMed Realty Trust, Inc. today announced that it has entered into definitive agreements to acquire five properties, comprised of 14 life science buildings with approximately 405,000 square feet of laboratory and office space, in San Diego's primary life science submarkets of University Towne Centre, Torrey Pines and Sorrento Valley.

8 Sep 2010

AHF praises US government's increase in PEPFAR funding commitment for Uganda

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, which currently cares for over 49,000 AIDS patients in Uganda through its Uganda CARES network of eleven treatment clinics throughout the country, today lauded the United States government for increasing its funding commitment in Uganda for the President's Emergency Plan for AIDS Relief (PEPFAR), the United States' respected global AIDS program.

8 Sep 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

8 Sep 2010

Quick-Med expands and strengthens NIMBUS technology intellectual property

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 7,790,217 entitled "Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate."

8 Sep 2010

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.

8 Sep 2010

Medical News

AIDS programs reach out to African immigrant community

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

Opinions: U.S. commitment to Global Fund; Innovative financing; Global food security; Aid for Pakistan

ResMed completes two-for-one stock split of common stock

Severe eye problems at cattle show

Flood victims in Pakistan helped by Australian health team

Neck manipulation may be risky without significant benefits: Study

Cocaine use on the rise in Australia

Shared needle at school science experiment puts students at risk

PositiveID to sell Health Link personal health record business to Health Plexus

OEFI selects HealthEdge's HealthRules product suite

BioSpace, Delaware BioScience partner to launch online career center for life science markets

NEXUS Biosystems acquires REMP from Tecan Group

Zyngenia completes $15M Series A financing extension from NEA

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

BioMed Realty Trust expands San Diego property portfolio to 1.8M rentable square feet

AHF praises US government's increase in PEPFAR funding commitment for Uganda

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

Quick-Med expands and strengthens NIMBUS technology intellectual property

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News